Antibody–drug conjugates (ADCs) harness the highly specific targeting capabilities of an
antibody to deliver a cytotoxic payload to specific cell types. They have garnered …

Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …

Proteins are the most abundant biomolecules within a cell and are involved in all
biochemical cellular processes, fulfilling specific functions with unmatched precision. This …

Combining the selective targeting of tumor cells through antigen-directed recognition and
potent cell-killing by cytotoxic payloads, antibody-drug conjugates (ADCs) have emerged in …

Proteins are multifunctional large organic compounds that constitute an essential
component of a living system. Hence, control over their bioconjugation impacts science at …

The bioconjugation of proteins—that is, the creation of a covalent link between a protein and
any other molecule—has been studied for decades, partly because of the numerous …

Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a
targeted cancer cell's death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T …

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating
cancer. Active targeting NPs can be generated by conjugation with ligands that bind …

Introduction: We discuss chemical conjugation strategies for antibody-drug conjugates
(ADCs) from an industrial perspective and compare three promising chemical conjugation …